The Journal of Steroid Biochemistry and Molecular Biology
Steroid inhibitorThe clinical development of a 5α-reductase inhibitor, finasteride
References (12)
- et al.
High-performance liquid chromatographic determination of N-(2-methyl-2-propyl 3-oxo-4 aza-5α-androst-1-ene-17b-carboxamide. A 4-Aza steroid in human plasma from a phase I study
J. Chromat.
(1988) - et al.
Mortality and reoperation after open and transurethral resection of the prostate of benign prostatic hyperplasia
New Engl. J. Med.
(1989) Biochemistry and pharmacology of 5α-reductase Inhibitors
- et al.
Familial incomplete male pseudohermaphroditism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias
New Engl. J. Med.
(1974) - et al.
Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism
Science
(1974) - et al.
Effect of MK-906, a specific 5α-reductase inhibitor on serum androgens and androgen conjugates in normal men
J. Androl.
(1989)
Cited by (217)
Neurosteroids and neuropathic pain management: Basic evidence and therapeutic perspectives
2019, Frontiers in NeuroendocrinologyAnti-androgenic therapy with finasteride improves cardiac function, attenuates remodeling and reverts pathologic gene-expression after myocardial infarction in mice
2018, Journal of Molecular and Cellular CardiologyCitation Excerpt :In this regard, we have recently demonstrated that the anti-androgenic medication finasteride, which is currently widely used in patients to counteract benign prostate hyperplasia, reduces cardiac hypertrophy and cardiac dysfunction in mice during experimental pressure overload by transverse aortic constriction (TAC) [15]. Finasteride acts by inhibiting the isoforms two and three of the 5-alpha reductase (Srd5a2, Srd5a3) that catalyze the generation of the highly active metabolite dihydrotestosterone (DHT) from testosterone, and that become induced in pressure overload hypertrophy in mice and in the myocardium of patients with heart failure [15] [16,17]. DHT is known to induce hypertrophy and we had observed increased DHT levels in hypertrophied mouse and human hearts [15,18].
5-Alpha-Reductase Inhibitors and Combination Therapy
2016, Urologic Clinics of North AmericaCitation Excerpt :According to current guidelines, both 5ARIs can be used in the treatment of BPH with lower urinary tract symptoms (LUTS), either alone or in combination with other drugs targeting BPH/LUTS.8,9 After several animal experiments, MK-906 (which later became FIN) was successfully tested for safety, tolerability, and biochemical activity in 350 volunteers.10 In healthy men, MK-906 reduced serum DHT levels by −62% to −82% without affecting serum testosterone levels.11,12
Evaluation of the 5α-reductase inhibitor finasteride on reproduction and gonadal development in medaka, Oryzias latipes
2015, General and Comparative EndocrinologyCitation Excerpt :If 5αR has a role in fish steroid biosynthesis and a function in fish androgen signaling, via DHT, then exposure to a 5αR inhibitor should induce anti-androgenic responses like those observed in higher vertebrates. Finasteride (FIN) is a type-2 5αR inhibitor and is a pharmaceutical used in the treatment of a number of human diseases including prostate cancer, benign prostate hyperplasia and male pattern baldness (Stoner, 1990). Type-2 5αR is primarily expressed in genital tissues (Azzouni et al., 2012).
Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain
2014, Progress in NeurobiologyCitation Excerpt :Furthermore, corrective AP treatment repaired VINC or OXAL-induced nerve tissue damages by restoring normal density of intraepidermal nerve fibers in hind paw intraplantar skins and control expression level of neurofilament 200 kDa in VINC- or OXAL-treated rat dorsal root ganglia and sciatic nerves (Meyer et al., 2010, 2011). It is also important to discuss our results showing that the inhibition of progesterone conversion into 5α-reduced metabolites (dihydroprogesterone and AP) by finasteride (Finn et al., 2006; Stoner, 1990) completely blocked antinociceptive, analgesic and neuroprotective effects exerted by progesterone against VINC-induced painful neuropathy. In fact, in the absence of finasteride, progesterone may be converted to the potent progesterone nuclear receptor agonist dihydroprogesterone (Brann et al., 1990) and to the neuroprotector AP (Melcangi et al., 2008), allowing therefore a strong stimulation or optimal activities of biochemical and neuroanatomical/neurochemical components in peripheral nerves such as CNPase, axonal constitutive proteins/transporters and intraepidermal nerve fibers (IENF).